Literature DB >> 8901012

The effects of ifenprodil and eliprodil on voltage-dependent Ca2+ channels and in gerbil global cerebral ischaemia.

C P Bath1, L N Farrell, J Gilmore, M A Ward, C A Hicks, M J O'Neill, D Bleakman.   

Abstract

Ifenprodil and eliprodil are both non-competitive NMDA receptor antagonists which have been shown to inhibit neuronal Ca2+ channel currents. We have examined the effects of these agents on two defined subtypes of voltage-dependent Ca2+ channels and in the gerbil model of global cerebral ischaemia. Recombinantly expressed human alpha 1B-1 alpha 2b beta 1-3 Ca2+ subunits in HEK293 cells, which results in an omega-conotoxin-sensitive neuronal N-type voltage-dependent Ca2+ channel and omega-Aga IVA sensitive Ca2+ channels (P-type) in acutely isolated cerebellar Purkinje neurones were reversibly inhibited by ifenprodil and eliprodil. Human N-type Ca2+ channel currents were inhibited by ifenprodil and eliprodil with IC50 values of 50 microM and 10 microM respectively whereas P-type Ca2+ channel currents were inhibited reversibly by ifenprodil and eliprodil with approximate IC50 values of 60 microM and 9 microM respectively. Maximum current block observed for both channel subtypes was approximately 80% for both ifenprodil and eliprodil. For neuroprotection studies, animals were subjected to 5 min bilateral carotid artery occlusion with or without administration of either ifenprodil or eliprodil (5, 10 or 20 mg/kg i.p.) immediately after surgery followed by two further doses (2.5, 5 or 10 mg/kg, respectively) at 3 and 6 h post-occlusion. Both compounds provided significant protective effects against ischaemia-induced neurodegeneration in the CA1 region of the hippocampus. These results indicate that both ifenprodil and eliprodil protect against ischaemia-induced neurodegeneration when administered post-occlusion and that they also block N and P-type voltage-dependent Ca2+ channels.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8901012     DOI: 10.1016/0014-2999(95)00846-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  NR2B-NMDA receptor-mediated increases in intracellular Ca2+ concentration regulate the tyrosine phosphatase, STEP, and ERK MAP kinase signaling.

Authors:  Surojit Paul; John A Connor
Journal:  J Neurochem       Date:  2010-05-28       Impact factor: 5.372

2.  The dextromethorphan analog dimemorfan attenuates kainate-induced seizures via sigma1 receptor activation: comparison with the effects of dextromethorphan.

Authors:  Eun-Joo Shin; Seung-Yeol Nah; Won-Ki Kim; Kwang Ho Ko; Wang-Kee Jhoo; Yong-Kwang Lim; Joo Young Cha; Chieh-Fu Chen; Hyoung-Chun Kim
Journal:  Br J Pharmacol       Date:  2005-04       Impact factor: 8.739

3.  Behavioral deficits and cellular damage following developmental ethanol exposure in rats are attenuated by CP-101,606, an NMDAR antagonist with unique NR2B specificity.

Authors:  B Lewis; K A Wellmann; A M H Kehrberg; M L Carter; T Baldwin; M Cohen; S Barron
Journal:  Pharmacol Biochem Behav       Date:  2011-10-20       Impact factor: 3.533

Review 4.  Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels.

Authors:  Kasper B Hansen; Lonnie P Wollmuth; Derek Bowie; Hiro Furukawa; Frank S Menniti; Alexander I Sobolevsky; Geoffrey T Swanson; Sharon A Swanger; Ingo H Greger; Terunaga Nakagawa; Chris J McBain; Vasanthi Jayaraman; Chian-Ming Low; Mark L Dell'Acqua; Jeffrey S Diamond; Chad R Camp; Riley E Perszyk; Hongjie Yuan; Stephen F Traynelis
Journal:  Pharmacol Rev       Date:  2021-10       Impact factor: 18.923

5.  Administration of eliprodil during ethanol withdrawal in the neonatal rat attenuates ethanol-induced learning deficits.

Authors:  J D Thomas; G G Garcia; H D Dominguez; E P Riley
Journal:  Psychopharmacology (Berl)       Date:  2004-04-03       Impact factor: 4.530

6.  Evaluation of 11C-NR2B-SMe and Its Enantiomers as PET Radioligands for Imaging the NR2B Subunit Within the NMDA Receptor Complex in Rats.

Authors:  Lisheng Cai; Jeih-San Liow; Cheryl L Morse; Sanjay Telu; Riley Davies; Michael P Frankland; Sami S Zoghbi; Ken Cheng; Matthew D Hall; Robert B Innis; Victor W Pike
Journal:  J Nucl Med       Date:  2020-01-10       Impact factor: 10.057

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.